18:09 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Cell culture studies suggest inhibiting KIF15 alone or in combination with KSP could help treat cancer. In HeLa cells, a tool compound KIF15 inhibitor decreased proliferation compared with no treatment, and the KIF15 inhibitor...
07:00 , Oct 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ring finger protein 20 (RNF20); RNF40; kinesin spindle protein (KSP; Eg5; KIF11)

Cancer INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting RNF20, RNF40 or KSP could help treat breast cancer. In a human breast adenocarcinoma cell line, siRNA targeting RNF20, RNF40 or KSP increased apoptosis and decreased...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Company News

4SC, Link Health deal

4SC granted Link Health exclusive rights to develop and commercialize 4SC-205 in Taiwan and China, including Hong Kong and Macau. Link Health will be responsible for clinical development of the oral inhibitor of ...
01:19 , Jun 1, 2016 |  BC Extra  |  Company News

Link gets China rights to 4SC cancer candidate

4SC AG (Xetra:VSC) granted Link Health Group (Guangzhou, China) exclusive rights to oncology candidate 4SC-205 in China, Hong Kong, Taiwan and Macau. Link Health will be responsible for clinical development of the oral inhibitor of...
07:00 , Oct 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Kinesin spindle protein (KSP; Eg5; KIF11)

Cancer INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest KSP inhibitors could help treat glioblastoma. Levels of KSP were higher in tumor samples from glioblastoma patients than in brain tissue from epilepsy patients who...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Clinical News

4SC-205: Phase I final data

Final data from the open-label, dose-escalation, German Phase I AEGIS trial in 59 patients with advanced solid tumors showed that the recommended Phase II dose of oral 4SC-205 is 20 mg once daily. That dose...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Financial News

Megakaryon completes venture financing

Megakaryon Corp., Kyoto, Japan   Business: Hematology   Date completed: 2015-03-20   Type: Venture financing   Raised: Y2.6 billion ($21.1 million)   Investors: Innovation Network Corp. of Japan (INCJ); SMBC Capital; Mizuho Capital; Mitsubishi UFJ Capital Co.; Japan Asia Investment;...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Company News

Bind Therapeutics, Merck deal

The companies partnered to discover and develop nanomedicines using Bind's Medicinal Nanoengineering platform to create targeted Accurins based on payloads from Merck's preclinical oncology portfolio. Accurins are selective and programmable nanoparticle-encapsulated therapeutics, which are designed...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Financial News

Regimmune completes venture financing

Regimmune Corp., Tokyo, Japan   Business: Inflammation, Autoimmune, Transplant   Date completed: 2/14/14   Type: Venture financing   Raised: $9.2 million   Investors: Japan Asia Investment; Nippon Venture Capital; Mizuho Capital; Nissei Insurance; KSP; Mitsui-Sumitomo Insurance; SMBC Capital; Mitsubishi...
01:18 , Feb 15, 2014 |  BC Extra  |  Financial News

Regimmune raises $9.2 million in series D

Autoimmune and allergy company Regimmune Corp. (Tokyo, Japan) raised $9.2 million in a series D round led by Japan Asia Investment and Nippon Venture Capital. New investors Mizuho Capital; Nissei Insurance; KSP and Mitsui-Sumitomo Insurance...